Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25493847 | 0.79 | JAK2 (0.46) | JAK2BRAFCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL17873349 | 0.78 | JAK2 (0.44) | JAK2BRAFCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL17873407 | 0.77 | MEN1 (0.34) | BRAF | |
| SCHEMBL18103504 | 0.74 | LRRK2 (0.55) | JAK2FLT3PRKCQ | |
| SCHEMBL14883424 | 0.72 | JAK2 (0.54) | JAK2BRAFCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL22050653 | 0.71 | JAK2 (0.47) | JAK2BRAFCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL17873360 | 0.71 | CSNK2A1 (0.49) | JAK2CYP2C9CYP3A4CYP2C19LCK | |
| SCHEMBL28372964 | 0.69 | JAK2 (0.51) | JAK2BRAFCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL24780533 | 0.69 | JAK2 (0.51) | JAK2BRAFCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL14327594 | 0.69 | JAK2 (0.48) | JAK2BRAFCYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2025-06-26 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3237419-B1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3237419-B1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397798-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2020-12-24 | — | — | US | disclosed |
| US-10793577-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20190211026-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2019-07-11 | — | — | US | disclosed |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017205684-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2017-11-30 | — | — | WO | disclosed |
| EP-3237419-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Akarna Therapeutics, Ltd. (GB) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016103037-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016103037-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793577-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | JAK2 1155/4885BRAF 822/4885CYP2C9 3125/4885 |
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | JAK2 1155/4885BRAF 822/4885CYP2C9 3125/4885 |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | JAK2 1155/4885BRAF 822/4885CYP2C9 3125/4885 |
| US-20200397798-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | DPP4, TLR1, SLC5A1 | JAK2 552/4885BRAF 1224/4885CYP2C9 2630/4885 |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | JAK2 1155/4885BRAF 822/4885CYP2C9 3125/4885 |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | JAK2 1155/4885BRAF 822/4885CYP2C9 3125/4885 |
| US-20190211026-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | JAK2 1155/4885BRAF 822/4885CYP2C9 3125/4885 |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | JAK2 1155/4885BRAF 822/4885CYP2C9 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.